Leading CBD manufacturer British Cannabis has revealed that a total of 1,472 of its products have successfully passed onto the crucial next stage of the UK Novel Foods process for CBD food supplements.
Last week, the Food Standards Agency (FSA) has updated the CBD public list, adding almost 6,000 more CBD products to the list, taking the total number to 11,908. The agency added that the list is now closed and further requests to have products put on the public list or evidence sent are no longer being accepted.
With the publication of the list – a key stage on the path to full authorisation, expected next year – only those CBD products featured on the list can now stay on the market, in line with the UK’s Novel Food requirements.
With 1,472 unique products across many thorough applications, British Cannabis said it has the highest number of CBD food supplement products permitted for general sale of any brand or manufacturer.
This resulting 12.4 per cent share of the UK market by choice of products includes 75 of the company’s own-brand portfolio, from the CBD by British Cannabis (FKA Canabidol), Access CBD and CBD Health ranges. Also progressing on towards the validation stage are hundreds of individual products across several leading brands ‘Powered by British Cannabis’ under the company’s white label manufacturing services.
The products prominent in the FSA public list made by British Cannabis include sublingual CBD oils, CBD capsules, and edible food products such as CBD gummies and Gel-Tabs.
CBD by British Cannabis CBD oral capsules
“This is a monumental moment for our company and a recognition of three years of work and investment from myself and our dedicated project team,” Thomas Whettem, British Cannabis chief executive, said.
“Our aim from the start in 2015 has been to act as an authority when it comes to CBD products that people can trust. Now, having cornered the market with nearly 1-in-10 of the CBD products remaining legal to sell in the UK, I am galvanised that we are on our way to achieving this goal.”
David Ralson, British Cannabis managing director, added: “I can hardly put into words how excited and proud this announcement makes me, both for my team and for all of the customers that support our products. To be confirmed at this time as the most predominate manufacturer in the UK for the number of products on the FSA public list is gratifying for all of the dedication we have put into doing things the best way possible and in order to make our products sustainable for the future.”
Following on from the FSA announcement made on 30 June, the thousands of other products that are not present on the public list are recommended to be removed from sale in retailers across the UK, with Trading Standards set to roll out plans for enforcement in the coming weeks.
“I would encourage all of our customers and consumers, existing and future, to check the FSA public list carefully; is your CBD supplement on the list? If not, why? Our Primary Partnership with Berkshire & Buckinghamshire Trading Standards sees us ready to advise retailers who have questions about this process and what compliant CBD products they should be stocking,” Ralson said.
“Moving forward, we are delighted to be able to offer them a greater choice of compliant cannabis food products than any other manufacturer.”
British Cannabis noted that its products are among the few remaining on the market to use 100% cannabis, naturally derived formulas in their CBD oils; thus, they contain the hundreds of clinically proven plant phytochemicals found in cannabis whilst also being 0% THC. Their food supplements are also free from other restricted cannabinoids.
Panel discussion at the relaunch of the SAITG on 3 March 2025
